IBRX

ImmunityBio, Inc.

Phase 2 Estimated

N-803 (IL-15 Superagonist)

Long COVID

Countdown

117days

Phase 2 readout · ~ Oct 31, 2026 estimated

What's at stake Phase 2 trial results for N-803 (IL-15 Superagonist) in Long COVID are due ~ Oct 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · ClinicalTrials.gov verified 13h ago

“CT.gov NCT07108036: Phase 2 trial, sponsor ImmunityBio, Inc., drug N-803 (IL-15 Superagonist). Primary completion date 2026-10 (estimated).”

Add to calendar Post on X Reddit

Provenance